Conference Track

Treatment of HBV

Source: CCO Independent Conference Coverage of the 2004 Annual Meeting of The American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Hepatitis B Viral Dynamics in Telbivudine-treated Patients
Hepatitis B Progression Predicted by Baseline HBV DNA Level in HBeAg-Negative Patients With Normal ALT Levels
HBV Viral Load Predicts Risk of Advanced Liver Disease and HCC in HBsAg-positive Patients
Entecavir Resistance Appears to Require Lamivudine Resistance Mutations in Chronic HBV Patients
Histologic and Virologic Comparison Between Entecavir and Lamivudine in HBeAg-Negative Chronic HBV at 48-week Analysis
Peginterferon plus Lamivudine Superior to Lamivudine Alone for HBeAg-positive Patients With Chronic Hepatitis B
Emtricitabine Promising for Treatment of Chronic HBV
Entecavir Superior to Lamivudine in HBeAg-Positive Patients With Chronic HBV at 48 Weeks
Experimental Vaccine Allows Discontinuation of HBIg Prophylaxis for More than Half of Liver Transplant Patients in Pilot Study
Lamivudine Plus Adefovir dipivoxil Salvage for Preventing Post-transplant HBV Recurrence More Cost-effective Than Standard Lamivudine/HBIg
Entecavir Reduced HBV DNA Levels to a Greater Degree Than Did Lamivudine, Regardless of Baseline ALT Level
Clevudine for 24 Weeks Shows Greater Activity Against HBV Than 12 Weeks
Adefovir Plus Emtricitabine for HbeAg-Positive Chronic Hepatitis B
Improved Histology and HBV DNA Suppression With Entecavir in Lamivudine-Refractory, HBeAg-positive Chronic HBV
Sustained HBV Suppression Prevents Liver Decompensation, but Not HCC, in HBeAg-negative Cirrhotic Patients Taking Lamivudine
Lamivudine Effective for Acute, Severe Hepatitis B in Pilot Study

Expert Analysis

Treatment of HBV

Program Director: Patrick J. Lynch, MD

Faculty:

Geoffrey M. Dusheiko, MD, FCP(SA), FRCP
Emmet B. Keeffe, MD, MACP
Marion G. Peters, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the results of recent studies of antiviral agents for the treatment of chronic hepatitis B, including adefovir dipivoxil, entecavir, telbivudine, and lamivudine as well as peginterferon and standard interferon
Review approaches for avoiding the development of drug resistance during treatment of chronic hepatitis B, and for treating patients infected with lamivudine-resistant HBV
Discuss the prevention of vertical transmission of HBV

Earn CME credit by reading the expert analysis and commentary on Treatment of HBV.

Topics covered include:

Peginterferon
Entecavir
Entecavir Resistance and Lamivudine Resistance
Emtricitabine
Lamivudine and Vertical Transmission
Lamivudine
Other Agents: Adefovir, Telbivudine, and Clevudine
Miscellaneous Topics

CME CREDIT INFORMATION

Release Date: 12/09/04

Expiration Date: 12/08/05

Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Registered Nurses: 3.5 Nursing CE credits

Pharmacists: 3.0 contact hours (0.3 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.